No Data
No Data
Hong Kong Market Quick View | Hong Kong stocks soared across the board! The technology index surged over 5%; Network Technology stocks rose, with Tencent gaining over 7% and Xiaomi reaching a historic high again.
Network Technology stocks rose, Bilibili-W increased by 14.96%, and SenseTime-W rose by 7.69%; Biotechnology stocks rose, TIGERMED increased by 12.59%, and WUXI BIO rose by 11.75%; Mobile Game stocks strengthened, Bilibili-W rose by 14.96%, and TENCENT increased by 7.42%.
Hong Kong stock market midday review | All three major Indexes are up! The Science and Technology Index rises over 3%; tech and Digital Health stocks are all rising, with Tencent and Xiaomi both up over 4%, and ALI HEALTH rising over 16%.
Network Technology stocks rose, with JD-SW up 4.95% and Sensetime-W up 4.73%; Lithium Battery stocks also increased, with BYD Co., Ltd. up 7.37% and Zhongcheng Innovation falling 4.43%; Automotive stocks rose as well, with BYD Co., Ltd. up 7.37% and Great Wall Motor up 6.30%.
Daiwa: Maintains the "Buy" rating for BEIGENE (06160), with the Target Price raised to HKD 171.
Daiwa predicts that with the sales boost from Brukinsa, BEIGENE's revenue in the last quarter of last year increased by 65% year-on-year to 1.045 billion dollars.
Hong Kong stocks are moving | BEIGENE (06160) surged over 7% in early trading as Daiwa upgraded the sales forecast for zebutaline. Institutions state that the company is nearing a turning point in profitability.
BEIGENE (06160) rose over 7% in the early session, and as of publication, it was up 6.24% at 139.6 HKD, with a transaction volume of 0.148 billion HKD.
Major Ratings | Daiwa: Raises BEIGENE Target Price to HK$171, maintains "Buy" rating.
Gelonghui, February 14 | Daiwa released a report stating that driven by Brukinsa sales, BEIGENE's revenue in the fourth quarter of last year grew by 65% year-on-year to 1.045 billion USD, and R&D costs increased by 10% year-on-year to 0.545 billion USD. Daiwa upgraded its revenue forecasts for Brukinsa, raising the estimates for 2025 and 2026 by 7% and 4% to 3.5 billion USD and 4.2 billion USD respectively, primarily due to increased sales in the USA and Europe, as well as its leading product in the Global Bruton's tyrosine kinase (BTK) market and continuous market share growth. The recommendation for the stock remains 'Buy.'
Daiwa raises the Target Price of BEIGENE (06160.HK) to 171 yuan and adjusts the sales forecast for Brukinsa.
Daiwa released a report indicating that driven by Brukinsa sales, BEIGENE (06160.HK) is expected to achieve a 65% year-on-year revenue growth in the fourth quarter of last year to 1.045 billion USD. Research and development costs are projected to increase by 10% year-on-year to 0.545 billion USD. A net loss of 0.141 billion USD is anticipated, widening from a net loss of 0.121 billion USD in the third quarter of last year. Daiwa has raised its revenue forecasts for Brukinsa for 2025 and 2026, increasing them by 7% and 4% to 3.5 billion USD and 4.2 billion USD respectively, primarily due to its sales increase in the USA and Europe, as well as its Global sales of Bruton's tyrosine.